Immunomedics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immunomedics Inc (IMMU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immunomedics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-28.2% annualized vs trailing 12 months).
- Peer revenue share: Immunomedics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMMU Sales vs. its Competitors, Q2 2018
Immunomedics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 3.0% year over year, combined, vs -39.7% for Immunomedics Inc. Immunomedics Inc's share of combined industry revenue moved from 0.02% to 0.01%, a loss of 0.01 percentage points.
Immunomedics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immunomedics Inc | - | - | - | No |
| High-Confidence Competitors (61) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMMU Stock Performance relative to its Competitors
IMMU Stock Performance relative to High-Confidence Competitors
Immunomedics Inc's Competitors Named by the Company
Competitive relationships identified from Immunomedics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Autolus Therapeutics Plc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Intercept Pharmaceuticals | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Alfasigma S.p.A. | Company report | 85% |
| ENTO | Company report | 85% |
Company report basis, confidence, active dates and source counts for Immunomedics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Immunomedics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.